Generally, trastuzumab is well tolerated, however, cardiotoxicity remains the most debilitating complication that can manifest itself clinically by cardiac insufficiency sometimes requiring discontinuation of treatment and may compromise the vital prognosis of patients. However, unlike anthracycline-induced cardiac toxicity, the toxicity associated with trastuzumab usually responds to standard